Attorney Docket No. 10525.0015-00000

Application No.: 10/534,486

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the

application:

1-8. (Withdrawn)

9. (Currently amended) A The-screening method for a prophylactic or therapeutic

substance for diabetes or a renal disease, of claim 7, which comprises cultivating a cell

that contains an insulin gene or a gene under the control of an insulin promoter with

containing a gene whose expression is controlled by a protein comprising the same or

substantially the same amino acid sequence as the amino acid sequence shown by

SEQ ID NO:2 or a partial peptide thereof or a salt thereof with said protein or a partial

peptide thereof or a salt thereof in the presence and absence of a test substance, and

comparing the expressions expression level of the insulin gene or the gene under the

control of the insulin promoter in the presence and absence of the test substance, said-

gene-and selecting the test substance that changes the expression level of the insulin

gene or the gene under the control of the insulin promoter as a candidate for the

prophylactic or therapeutic substance.

10-12. (Withdrawn)

13. (Canceled)

-3-

Attorney Docket No. 10525.0015-00000

Application No.: 10/534,486

14. (Canceled)

15. (Currently amended) The screening method of claim 914, wherein the cell contains

a polynucleotide comprising comprises the entire or a portion of the base nucleotide

sequence shown by SEQ ID NO:1, which encodes the amino acid sequence shown by

SEQ ID NO:2.

16. (Canceled)

17. (Currently amended) The screening method of claim 944, wherein the renal disease

is diabetic nephropathy.

18. (Currently amended) A The screening method for a prophylactic or therapeutic

substance for diabetes or a renal disease, of claim 14, which comprises cultivating a cell

having an ability to produce a protein comprising the same or substantially the same

amino acid sequence as the amino acid sequence shown by SEQ ID NO:2 or a partial

peptide thereof or a salt thereof in the presence and absence of a test substance, and-

comparing the expression level amounts of the mRNA that encodes said protein or a

partial peptide thereof in the presence and absence of the test substance, under the two

conditions and selecting the test substance that changes the expression level of the

mRNA as a candidate for the prophylactic or therapeutic substance.

19-31. (Withdrawn)

-4-

Attorney Docket No. 10525.0015-00000

Application No.: 10/534,486

32-33. (Canceled)

34-35. (Withdrawn)

36-37, (Cancelled)

38. (New) The screening method of claim 9, wherein the test substance that increases the expression level of the insulin gene or the gene under the control of the insulin promoter is selected as a candidate for the prophylactic or therapeutic substance.

- 39. (New) The screening method of claim 9, wherein the cell is cultivated with a protein comprising the amino acid sequence shown by SEQ ID NO:2 or a salt thereof.
- 40. (New) The screening method of claim 9, wherein the cell has the ability to produce a protein comprising the amino acid sequence shown by SEQ ID NO:2 or a salt thereof.
- 41. (New) The screening method of claim 18, wherein the test substance that decreases the expression level of the mRNA is selected as a candidate for the prophylatic or therapeutic substance.

Attorney Docket No. 10525.0015-00000 Application No.: 10/534,486

42. (New) The screening method of claim 18, wherein the cell has the ability to produce a protein comprising the amino acid sequence shown by SEQ ID NO:2 or a salt thereof.

43. (New) The screening method of claim 18, wherein the renal disease is diabetic nephropathy.